APA (7th ed.) Citation

Chen, Z., Fu, X., Zhu, L., Wen, X., & Zhang, S. (2024). The benefit and risk of addition of chemotherapy to EGFR tyrosine kinase inhibitors for EGFR-positive non-small cell lung cancer patients with brain metastases: A meta-analysis based on randomized controlled trials. Frontiers in oncology, 14, 1448336. https://doi.org/10.3389/fonc.2024.1448336

Chicago Style (17th ed.) Citation

Chen, Zhigang, Xiang Fu, Lingping Zhu, Xiurong Wen, and Shihao Zhang. "The Benefit and Risk of Addition of Chemotherapy to EGFR Tyrosine Kinase Inhibitors for EGFR-positive Non-small Cell Lung Cancer Patients with Brain Metastases: A Meta-analysis Based on Randomized Controlled Trials." Frontiers in Oncology 14 (2024): 1448336. https://doi.org/10.3389/fonc.2024.1448336.

MLA (9th ed.) Citation

Chen, Zhigang, et al. "The Benefit and Risk of Addition of Chemotherapy to EGFR Tyrosine Kinase Inhibitors for EGFR-positive Non-small Cell Lung Cancer Patients with Brain Metastases: A Meta-analysis Based on Randomized Controlled Trials." Frontiers in Oncology, vol. 14, 2024, p. 1448336, https://doi.org/10.3389/fonc.2024.1448336.